trial

Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis

NCTId NCT02459210
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 58 (actual)
Sponsored by Beth Israel Deaconess Medical Center
Primary completion 2019-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
58 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2015-01
Primary completion
2019-01
Eligibility
ALL · 16 Years · 25 Years

Interventions & indications

Drugs
CLUEStherapy and computer games

Sponsors

Beth Israel Deaconess Medical CenterLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Matcheri S. Keshavan, MDPrincipal Investigator

Sites

1 total
Boston, United States

Facts & assertions

4 sourced
Enrollment
58
Phase
NA
Primary Completion Date
2019-01
Status
COMPLETED
relationships
The graph out of here
drug
CLUES
drug
therapy and computer games
drug
lead_sponsor
Beth Israel Deaconess Medical Center
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Psychosis
indication
Psychotic Disorders
indication
investigator
Matcheri S. Keshavan, MD
person